As of close of business last night, Oramed Pharmaceuticals Inc.’s stock clocked out at $2.08, up 0.48% from its previous closing price of $2.07. In other words, the price has increased by $+0.0100 from its previous closing price. On the day, 961680 shares were traded. ORMP stock price reached its highest trading level at $2.1000 during the session, while it also had its lowest trading level at $1.9900.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
To gain a deeper understanding of ORMP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.50 and its Current Ratio is at 24.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Canaccord Genuity on January 12, 2023, Downgraded its rating to Hold and sets its target price to $3 from $30 previously.
On February 18, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On April 20, 2021, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $27.Canaccord Genuity initiated its Buy rating on April 20, 2021, with a $27 target price.
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 03 when Rabinowitz Michael sold 13,325 shares for $12.55 per share. The transaction valued at 167,195 led to the insider holds 126,143 shares of the business.
RAKIN KEVIN sold 10,000 shares of ORMP for $94,096 on Mar 21. The Director now owns 46,661 shares after completing the transaction at $9.41 per share.
For the stock, the TTM Price-to-Sale (P/S) ratio is 27.93 while its Price-to-Book (P/B) ratio in mrq is 0.53.
Stock Price History:
Over the past 52 weeks, ORMP has reached a high of $13.73, while it has fallen to a 52-week low of $1.81. The 50-Day Moving Average of the stock is 7.0058, while the 200-Day Moving Average is calculated to be 6.7817.
It appears that ORMP traded 1.51M shares on average per day over the past three months and 1.52M shares per day over the past ten days. A total of 39.10M shares are outstanding, with a floating share count of 37.06M. Insiders hold about 4.80% of the company’s shares, while institutions hold 10.10% stake in the company. Shares short for ORMP as of Oct 13, 2022 were 3M with a Short Ratio of 2.75M, compared to 2.96M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.72% and a Short% of Float of 7.99%.
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.3, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.01 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.72 and -$1.25 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$1.13, with 5 analysts recommending between -$0.85 and -$1.42.
A total of 6 analysts have provided revenue estimates for ORMP’s current fiscal year. The highest revenue estimate was $3.61M, while the lowest revenue estimate was $2.69M, resulting in an average revenue estimate of $2.88M. In the same quarter a year ago, actual revenue was $904k, up 218.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $2.82M in the next fiscal year. The high estimate is $3.2M and the low estimate is $2.7M. The average revenue growth estimate for next year is down -2.10% from the average revenue estimate for this year.